About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Signup For Free
Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025
Cerevance announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025. Key presentations include Phase 1 dat...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025